Investigation Report on China Insulin Lispro Market, 2009-2018 - PowerPoint PPT Presentation

About This Presentation
Title:

Investigation Report on China Insulin Lispro Market, 2009-2018

Description:

Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. – PowerPoint PPT presentation

Number of Views:55

less

Transcript and Presenter's Notes

Title: Investigation Report on China Insulin Lispro Market, 2009-2018


1
Investigation Report on China Insulin Lispro
Market, 2009-2018
One-Stop Shop for Business Information
2
Summary
According to IDF (the International Diabetes
Federation), incidence of diabetes among adults
aged 20-79 in the world was 8.3 in 2013 with 382
million patients worldwide. The number of
diabetes patients in China was more than 98
million, ranking the first in the world. The
rapid growth of diabetes patients is becoming a
serious economic and social issue in China and
other developing countries. The first
ultra-short-acting human insulin analogue insulin
lispro (produced by Eli Lilly and Company with
the trade name ""Humalog"") was launched in 1996
and approved by FDA.
3
Insulin lispro is a fast acting insulin analogue
with one primary advantage over regular insulin
for postprandial glucose control. It has a
shortened delay of onset, allowing slightly more
flexibility than regular insulin, which requires
a longer waiting period before starting a meal
after injection. In 2012, global sales revenue of
Humalog reached nearly USD 2.4 billion. Humalog
was launched in China in 2005 and its annual
sales revenue continues to grow rapidly.
According to CRI's investigation on certain
Chinese sample hospital market, the sales revenue
of insulin lispro in Chinese hospitals grew more
than 100 times from 2005 to 2013.
4
Most of the market is occupied by Eli Lilly and
Company while the other belongs to Gan Lee
Pharmaceuticals. There used to be legal disputes
between the two companies over the patent of
insulin lispro in China. Based on CRI's
investigation, insulin lispro produced by other
Chinese enterprises will soon appear on the
market. Incidence of diabetes continues to rise
in China as life improves and lifestyle changes.
IDF predicts that the number of diabetes patients
in China will reach 143 million in 2035, which is
still top of the world. Since market size of
insulin lispro is growing rapidly in China, huge
potential exists in the market.
5
Through this report, the readers can acquire the
following information-Incidence of Diabetes in
China-Market Share of Major Insulin Lispro
Manufacturers in Sample Hospitals in China-Sales
Price of Insulin Lispro in Hospital Market in
ChinaPatent Status of Insulin Lispro in
China-Production Status of Insulin Lispro in
China-Major Insulin Lispro Enterprises in
China The following enterprises and people are
recommended to purchase this report-Anti-diabeti
c Drug Manufacturers-Medical Institutions -Invest
ors /Research Agencies Focusing on Anti-diabetic
Drug Market
6
Table of Contents
  1. Table of Contents
  2. Relevant Concepts of Insulin Lispro
  3. Market Overview of Insulin Lispro in China
  4. Investigation on Sales Value of Insulin Lispro in
    China, 2009-2013
  5. Investigation on Market Share of Major Insulin
    Lispro Manufacturers in China, 2009-2013
  6. Investigation on Market Size of Insulin Lispro by
    Dosage Form in China, 2009-2013
  7. Reference Price of Insulin Lispro Produced by
    Different Enterprises in China Hospital Market,
    2014
  8. Major Manufacturing Enterprises in China Insulin
    Lispro Market, 2009-2013
  9. Prospect of China Insulin Lispro Market, 2014-2018

7
Related Reports
  • Central and Eastern Europe OTC Drugs Industry
    Outlook to 2017- Expanding Access to Distribution
    Channels to Lead Sales Growth
  • Russia Over-the-counter (OTC) Drugs Industry
    Outlook to 2017- Driven by Rising Ageing
    Population
  • Over-the-Counter (OTC) Drugs and Dietary
    Supplements Global Markets
  • Global Osteoporosis Drugs Market 2014-2018
  • Global Markets for Generic Drugs

8
Custom Research
  • Incase the reports dont match your
    requirement then we can do a Custom Research for
    you. Our multifarious capabilities, cross-sector
    expertise and detailed knowledge of various
    markets, put us at a unique position to take up
    Custom Research demands of yours. We provide the
    specifications of the custom research job to a
    dedicated team comprising of researchers,
    analysts and industry experts, who have close
    experience and understanding of global markets,
    competitive landscapes, various business models,
    market shares, drivers, restraints and
    benchmarks.
  • http//www.bharatbook.com/customResearch.asp

9
For More Information You Can Visit
  • http//www.bharatbook.com/healthcare-market-resear
    ch-reports-482745/investigation-report-on-china-in
    sulin-lispro-market-2009-2018.html

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 For Live
Chat - http//bit.ly/19m3TU4
Follow/Like Us on-
Write a Comment
User Comments (0)
About PowerShow.com